Beximco Pharma. - Q1 Financial Results 2025-26
24 June 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Q1 Financial Results 2025-26
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three-month period ended 30 September 2025.
Financial Highlights (Consolidated)
First quarter ended 30 September 2025
· Net revenue increased 17.8% to Bangladesh Taka ("BDT") 13,794.8m / £85.0m (2023-24: BDT 11,714.0m / £74.0m
o Domestic sales increased 17.8% to BDT 13,717.4m / £84.5m (2023-24: BDT 11,640.6m / £73.6m)
o Export sales increased 5.4% to BDT 77.4m / £0.5m (2023-24: BDT 73.4m / £0.5m)
· Profit after tax increased 41.9% to BDT 2,401.3m / £14.8m (2023-24: BDT 1,691.9m / £10.7m)
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For a summary of financial and operational highlights for the period from 1 January 2025 to 31 March 2026, please refer to the previous announcement titled: "Financial Results for the Periods from 1 January 2025 to 31 March 2026", released today.
Exchange rates of £1=Taka 162.3035 for 30 September 2025 and £1=Taka 158.2481 for 30 September 2024 have been used in this announcement.
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S M Rabbur Reza, Chief Operating Officer
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Simon Conway / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at September 30, 2025
September 30,
2025
Taka '000
June 30, 2025
ASSETS
Non-current assets
49,883,483
49,461,242
Property, plant and equipment
43,981,153
43,541,872
Right-of-use assets
463,968
485,613
Intangible assets
4,707,354
4,694,134
Deferred tax asset
35,464
44,079
Goodwill
674,570
674,570
Other investments
20,974
20,974
Current assets
25,986,643
23,786,005
Inventories
14,234,467
13,586,476
Spares and supplies
804,369
799,644
Trade and other receivables
3,724,128
3,628,788
Loans, advances, deposits and prepayments
3,191,326
2,814,492
Advance income tax
383,233
356,508
Short term investment
1,000,000
900,000
Cash and cash equivalents
2,649,120
1,700,097
TOTAL ASSETS
75,870,126
73,247,247
SHAREHOLDERS' EQUITY AND LIABILITIES
Equity attributable to the owners of the company
55,470,457
53,107,137
Share capital
4,461,121
4,461,121
Share premium
5,269,475
5,269,475
Excess of issue price over face value of GDRs
1,689,637
1,689,637
Capital reserve on merger
294,951
294,951
Revaluation surplus
1,133,107
1,133,870
Unrealized gain/(loss)
18,149
18,149
Retained earnings
42,604,017
40,239,934
Non-controlling interest
4,015,661
3,977,499
TOTAL EQUITY
59,486,118
57,084,636
Non-current liabilities
8,105,401
7,769,471
Long term borrowings-net of current maturity
1,271,390
1,503,595
Liability for gratuity, pension and WPPF
4,251,222
3,690,096
Deferred tax liability
2,582,789
2,575,780
Current liabilities
8,278,607
8,393,140
Short term borrowings
2,033,371
2,025,394
Long term borrowings-current maturity
1,200,490
1,436,752
Trade and other payables
2,823,065
2,925,994
Accrued expenses
1,275,791
1,174,096
Dividend payable
138,414
302,272
Income tax payable
807,476
528,632
TOTAL LIABILITIES
16,384,008
16,162,611
TOTAL EQUITY AND LIABILITIES
75,870,126
73,247,247
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July-September 2025
Taka '000
July - September 2025
July - September
2024
Net revenue
13,794,829
11,713,850
Cost of goods sold
(7,132,749)
(6,305,742)
Gross profit
6,662,080
5,408,108
Operating expenses
(3,368,334)
(2,845,000)
General and administrative expenses
(354,695)
(304,448)
Selling, marketing and distribution expenses
(3,013,639)
(2,540,552)
Profit from operations
3,293,746
2,563,108
Other income
169,395
20,061
Finance cost
(186,310)
(278,444)
Profit before tax and WPPF
3,276,831
2,304,725
Contribution to WPPF
(157,156)
(110,840)
Profit before tax
3,119,675
2,193,885
Income tax expenses
(718,414)
(502,003)
Current tax
(702,569)
(500,129)
Deferred tax
(15,845)
(1,874)
Profit after tax
2,401,261
1,691,882
Profit/(loss) attributable to:
Owners of the Company
2,363,099
1,680,570
Non-controlling interest
38,162
11,312
2,401,261
1,691,882
Other comprehensive income/(loss)
-
-
Total comprehensive income
2,401,261
1,691,882
Total comprehensive income attributable to:
Owners of the Company
2,363,099
1,680,570
Non-controlling interest
38,162
11,312
2,401,261
1,691,882
Earnings per share (EPS)
5.30
3.77
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July-September 2025
For the period ended September 2025
Taka '000
Share capital
Share premium
Excess of issue price over Face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2025
4,461,121
5,269,475
1,689,637
294,951
1,133,870
18,149
40,239,934
53,107,137
3,977,499
57,084,636
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
2,363,099
2,363,099
38,162
2,401,261
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(984)
-
984
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
221
-
-
221
-
221
Balance as on September 30, 2025
4,461,121
5,269,475
1,689,637
294,951
1,133,107
18,149
42,604,017
55,470,457
4,015,661
59,486,118
Net asset value (NAV) per share
Tk.
124.34
For the period ended September 2024
Share capital
Share premium
Excess of issue price over Face value of GDRs
Capital reserve on merger
Revaluation surplus
Unrealized gain/(loss)
Retained earnings
Equity attributable to owners of the company
Non-controlling interest
Total equity
Balance as on July 01, 2024
4,461,121
5,269,475
1,689,637
294,951
1,137,306
18,148
35,079,327
47,949,965
3,952,938
51,902,903
Total comprehensive income:
Profit/(loss) for the period
-
-
-
-
-
-
1,680,570
1,680,570
11,312
1,691,882
Others:
Adjustment for depreciation on revalued assets
-
-
-
-
(1,108)
-
1,108
-
-
-
Adjustment for deferred tax on revalued assets
-
-
-
-
249
-
-
249
-
249
Balance as on September 30, 2024
4,461,121
5,269,475
1,689,637
294,951
1,136,447
18,148
36,761,005
49,630,784
3,964,250
53,595,034
Net asset value (NAV) per share
Tk.
111.25
Beximco Pharmaceuticals Limited and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July-September 2025
July - September 2025
Taka '000
July - September 2024
Cash flows from operating activities
Cash receipts from customers and others
13,822,950
11,572,484
Cash paid to suppliers and employees
(10,498,856)
(9,346,118)
Cash generated from operations
3,324,094
2,226,366
Interest paid
(199,501)
(264,266)
Interest received
63,704
14,706
Income tax paid
(450,451)
(279,687)
Net cash generated from operating activities
2,737,846
1,697,119
Cash flows from investing activities
Acquisition of property, plant and equipment
(984,442)
(310,588)
Intangible assets
(92,909)
(27,560)
Disposal of property, plant and equipment
-
12,084
Short term investment
(100,000)
(250,000)
Net cash used in investing activities
(1,177,351)
(576,064)
Cash flows from financing activities
Net increase/(decrease) in long term borrowings
(463,728)
(219,109)
Net increase/(decrease) in short term borrowings
7,978
(903,361)
Dividend paid
(163,858)
(1,293)
Net cash from/(used in) financing activities
(619,608)
(1,123,763)
Increase/(decrease) in cash and cash equivalents
940,887
(2,708)
Opening cash and cash equivalents
1,700,097
854,106
Effect of exchange rate changes on cash and cash equivalents
8,136
7,967
Closing cash and cash equivalents
2,649,120
859,365
Net operating cash flows per share
6.14
3.80
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDQRFSEAFMDEMSEDM
